Favorites Sign in

One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
  1. Home
  2. Companies
  3. Zhongchao
  4. Financial Statements
  5. Income Statement
Zhongchao logo
Zhongchao ZCMD
$ 0.94 -2.08%
report update icon

Quarterly report 2025-Q4
added 10-30-2026

Zhongchao Income Statement 2025-2011 | ZCMD

Brief overview of revenue and earnings at Zhongchao

The conclusions below are based on five years of reported results. Zhongchao reported revenue of 18 million dollars in 2020 and 11.4 million dollars by 2025. Across the full period, sales moved by −36.8%; the average annual rate was −8.8%. The decline points to a contraction in the scale of the business.

Gross profit was 11.9 million dollars at the start and 5.1 million dollars at the end of the period (−56.9%). The cost base moved against the top-line trend and weighed on the gross result. The gross margin was 66% at the start and 45% at the end. Weakening gross profitability reduces the quality of the top-line trend.

The operating result measured by EBITDA moved from $4.7 million to −$5.9 million, or −226.5%. EBITDA underperformed the top-line trend. EBITDA margin moved from 25.9% to −51.9%. The business retained less EBITDA from each unit of revenue.

Across the five years, the net result shifted from 4.5 million dollars to −6.3 million dollars. Profit turned into a loss, the most concerning signal in the results.

The market value of the business moved from $44.7 million to $6.8 million, or −84.8%. Capitalization grew more slowly than the underlying results.

What the figures show

The financial trajectory is weak and requires a cautious interpretation. The main areas of concern are a declining EBITDA margin, a softer top-line trend and a low EBITDA margin. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.

Annual Income Statement Zhongchao

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

 6.8 M 846 K 462 K 2.96 M 4.04 M 44.7 M 24.6 M 23.7 M 22.3 M - - - - - -

Shares

 3.42 M 651 K 325 K 2.6 M 2.49 M 24.4 M 21.6 M 20.8 M 19.6 M - - - - - -

Historical Prices

 1.99 1.3 1.42 1.14 1.62 1.83 - - - - - - - - -

Net Income

 -6.31 M -643 K -11.3 M -2.94 M 239 K 4.46 M 4.05 M 3.02 M 1.53 M - - - - - -

Revenue

 11.4 M 15.9 M 19.4 M 14.2 M 16.3 M 18 M 14.9 M 12.9 M 9.82 M - - - - - -

Cost of Revenue

 6.25 M 6.95 M 10.9 M 7.79 M 6.86 M 6.12 M 4.66 M 4.46 M 3.97 M - - - - - -

Gross Profit

 5.12 M 8.91 M 8.51 M 6.36 M 9.44 M 11.9 M 10.2 M 8.41 M 5.85 M - - - - - -

Operating Income

 -6.19 M -341 K -13.3 M -2.95 M -321 K 4.49 M 3.64 M - - - - - - - -

Interest Expense

 79.4 K 160 K 1.07 M 262 K 34 K 306 K 534 K 37.4 K 275 K - - - - - -

EBITDA

 -5.9 M -110 K -12.8 M -2.57 M 20.9 K 4.67 M 3.72 M 23.7 K 13.1 K - - - - - -

Operating Expenses

 11.3 M 9.25 M 21.8 M 9.31 M 9.76 M 7.38 M 6.58 M 5.13 M 4.8 M - - - - - -

General and Administrative Expenses

 9.81 M 4.99 M 6.7 M 99.2 K 99.8 K 74.9 K 67.1 K 1.43 M 1.14 M - - - - - -

All numbers in USD currency

Quarterly Income Statement Zhongchao

2025-Q4 2025-Q2 2024-Q4 2024-Q2 2023-Q4 2023-Q2 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

 3.42 M 25.4 M 651 K 2.64 M 325 K 26 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

 -6.31 M -965 K -643 K 90 K -11.3 M -4.78 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

 11.4 M 5.6 M 15.9 M 8.35 M 19.4 M 10.4 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

 6.25 M 2.89 M 6.95 M 3.61 M 10.9 M 6.05 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

 5.12 M 2.71 M 8.91 M 4.74 M 8.51 M 4.32 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

 -6.19 M -879 K -341 K -51.6 K -13.3 M -6.02 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

 79.4 K 93.2 K 160 K 101 K 1.07 M 785 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

 -5.9 M -724 K -110 K 43 K -12.8 M -6.02 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

 11.3 M 3.59 M 9.25 M 4.79 M 21.8 M 10.3 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

 9.81 M 2.72 M 4.99 M 2.64 M 6.7 M 4.64 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Zhongchao (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Health information services industry

Issuer Price % 24h Market Cap Country
Signify Health Signify Health
SGFY
 		- -0.02 % $ 7.21 B usaUSA
Tabula Rasa HealthCare Tabula Rasa HealthCare
TRHC
 		- - $ 255 M usaUSA
OptimizeRx Corporation OptimizeRx Corporation
OPRX
 		$ 9.34 -1.37 % $ 173 M usaUSA
Change Healthcare Change Healthcare
CHNG
 		- - $ 9.03 B usaUSA
Cerner Corporation Cerner Corporation
CERN
 		- - $ 27.9 B usaUSA
10x Genomics 10x Genomics
TXG
 		$ 62.88 -3.34 % $ 7.84 B usaUSA
Veeva Systems Veeva Systems
VEEV
 		$ 306.1 -0.1 % $ 50.1 B usaUSA
SCWorx Corp. SCWorx Corp.
WORX
 		$ 1.31 -5.76 % $ 9.53 M usaUSA
HealthStream HealthStream
HSTM
 		$ 28.69 -0.14 % $ 861 M usaUSA
Accolade Accolade
ACCD
 		- 0.29 % $ 206 M usaUSA
Allscripts Healthcare Solutions Allscripts Healthcare Solutions
MDRX
 		- -10.39 % $ 886 M usaUSA
NantHealth NantHealth
NH
 		- -46.64 % $ 10.4 M usaUSA
Covetrus Covetrus
CVET
 		- - $ 2.94 B usaUSA
NextGen Healthcare NextGen Healthcare
NXGN
 		- - $ 1.6 B usaUSA
1Life Healthcare 1Life Healthcare
ONEM
 		- - $ 3.37 B usaUSA
iCAD iCAD
ICAD
 		- - $ 102 M usaUSA
R1 RCM R1 RCM
RCM
 		- - $ 3.81 B usaUSA
So-Young International So-Young International
SY
 		$ 2.0 0.5 % $ 156 M chinaChina
American Well Corporation American Well Corporation
AMWL
 		$ 12.0 -3.73 % $ 193 M usaUSA
Evolent Health Evolent Health
EVH
 		$ 4.79 1.7 % $ 547 M usaUSA
GoodRx Holdings GoodRx Holdings
GDRX
 		$ 3.54 -3.01 % $ 1.26 B usaUSA
Castlight Health, Inc. Castlight Health, Inc.
CSLT
 		- -7.28 % $ 227 M usaUSA
HMS Holdings Corp. HMS Holdings Corp.
HMSY
 		- - $ 3.29 B usaUSA
Inovalon Holdings, Inc. Inovalon Holdings, Inc.
INOV
 		- - $ 6.37 B usaUSA
Health Catalyst Health Catalyst
HCAT
 		$ 1.46 -3.31 % $ 102 M usaUSA
HealthEquity HealthEquity
HQY
 		$ 103.68 1.53 % $ 8.93 B usaUSA
Omnicell Omnicell
OMCL
 		$ 35.87 -3.96 % $ 1.65 B usaUSA
Progyny Progyny
PGNY
 		$ 36.44 1.35 % $ 3.11 B usaUSA
Schrödinger Schrödinger
SDGR
 		$ 32.42 -2.89 % $ 2.38 B usaUSA
Teladoc Health Teladoc Health
TDOC
 		$ 8.96 -0.28 % $ 1.58 B usaUSA
Computer Programs and Systems Computer Programs and Systems
CPSI
 		- 4.4 % $ 133 M usaUSA
Phreesia Phreesia
PHR
 		$ 13.15 1.94 % $ 786 M usaUSA
Akerna Corp. Akerna Corp.
KERN
 		- - $ 161 M usaUSA
MTBC MTBC
MTBC
 		- -0.58 % $ 51.7 M usaUSA
Premier Premier
PINC
 		- - $ 2.33 B usaUSA
Streamline Health Solutions Streamline Health Solutions
STRM
 		- - $ 21.4 M usaUSA